Key result
The bioprosthetic total artificial heart achieved a 72.7% primary composite success rate at 180 days, exceeding the prespecified 38% historical threshold.
Answers are grounded in this paper and cite their sources.
Demonstrates high 180-day survival with a bioprosthetic artificial heart in severe biventricular failure, indicating an effective bridge to transplantation.
Background and Aims Refractory advanced biventricular heart failure (RAHF) has a poor prognosis, and many patients are ineligible for left ventricular assist device (LVAD) support. The "historical" total artificial heart (TAH) is associated with high rates of stroke, bleeding, and haemolysis. The bioprosthetic TAH (bio-TAH), a pulsatile, autoregulated, and haemocompatible device, was assessed here as a bridge to transplantation. Methods EFICAS (NCT04475393) was a prospective, multicentre trial conducted at 10 French centres. Adults with RAHF who were ineligible for LVAD support and listed or eligible for heart transplantation were enrolled. The primary composite endpoint was survival at 180 days free from disabling stroke, device malfunction requiring reoperation or urgent transplantation, or elective heart transplantation. Secondary endpoints included serious adverse events, NYHA class, the 6-min walk test, and quality of life measured using the EQ-5D-5L. Results Fifty-five patients underwent implantation (December 2022 and May 2025; median age, 56 years [IQR, 48–63]; 49% INTERMACS profiles 1–2; 36% on VA-ECMO). The primary endpoint was achieved in 40 patients (72.7%; 95% confidence interval, 57.1–85.1), exceeding the prespecified “historical TAH” threshold of 38% (p<0.0001). At 180 days, 96% were free of disabling stroke, 76% were discharged, and 92% were NYHA class I-II. Median 6-minute walk distance improved by 305 m (p=0.0002) and EQ-5D by 40 points (p<0.0001). No haemolysis occurred, and major bleeding was limited to the first 30 days. Conclusions The bio-TAH achieved its primary endpoint with a favourable safety profile, supporting its use as an effective bridge-to-transplant strategy in patients with RAHF ineligible for LVAD support.
No takes yet. Share an insight, caveat, or question.
Vincentelli et al. (2026) studied Refractory advanced biventricular heart failure (RAHF) (n=55). Bioprosthetic total artificial heart (bio-TAH) vs. Historical TAH threshold was evaluated on survival at 180 days free from disabling stroke, device malfunction requiring reoperation or urgent transplantation, or elective heart transplantation (95% CI 57.1-85.1, p=<0.0001). The bioprosthetic total artificial heart achieved a 72.7% primary composite success rate at 180 days, exceeding the prespecified 38% historical threshold.
Synapse has enriched 10 related papers. Consider them for comparative context: